<DOC>
	<DOCNO>NCT02904213</DOCNO>
	<brief_summary>An open label , non-comparative bridging study evaluate safety pentavalent vaccine ComBe Five ( Liquid ) make India , healthy Vietnamese child age 8 - 10 week 3-dose series , interval dose 4 week</brief_summary>
	<brief_title>Evaluate Safety ComBe Five ( Liquid ) Healthy Vietnamese Children Aged From 8 - 10 Weeks 3-dose Series , Interval Each Dose 4 Weeks</brief_title>
	<detailed_description>The trial bridging Study evaluate safety pentavalent vaccine ComBe Five ( Liquid ) make India , healthy Vietnamese child age 8 - 10 week 3-dose series , interval dose 4 week . 330 subject enrol Binh Luc Ly Nhan district , Ha Nam province . These subject receive 3 dos ( 0.5ml/dose ) ComBe Five ( Liquid ) , first dose administer 8-10 week age . The frequency , rate severity immediate adverse event within 30 minute vaccination , solicit unsolicited AE within 28 day vaccination , frequency rate SAE within 28 day first vaccination record evidence ComBeFive ( Liquid ) safety assessment . The subject include trial would representative population Vietnam . The protocol review approve Vietnam Military Medical University IRB Vietnam Ministry Health IEC Vietnam Minister Health .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject must meet criterion participate study : 1 . Healthy child , gender , age 8 12 week screen visit first dose ( visit 1 ) 2 . Weight ≥ 3.300 gram Screening visit receive first dose 3 . Understand follow study 4 . Mother child serum negative HIV , HBV HCV blood test result antenatal test report book . 5 . Children mother n't participate clinical study schedule study . 6 . Parent/ legal guardian understand ability follow protocol . 7 . Parent/ legal guardian voluntary write consent participate study . 8 . Parent/ legal guardian subject ability comply process study . 9 . Parent/ legal guardian subject intend remain area participant study period . Subject one criterion must participate study : 1 . Fever ( temperature ≥37.5oC ) lose temperature ( ≤35.5 oC ) disease/ infection chronic 2 . Subjects receive DPT 3 . Subjects receive immunosuppressant therapy 4 . Subjects know doubt hypersensitivity allergic reaction component study vaccine 5 . Subjects sign symptom functional disorder , especially central nervous system . 6 . Subjects haemophilia receive treatment anticoagulant drug , risk serious bleed intramuscular injection . 7 . Subjects family history SIDS ( Sudden Infant death syndrome ) 8 . Subjects intend surgery schedule study 9 . Subjects receive blood product , corticosteroid cytotoxic drug , radiotherapy . 10 . Subjects mother participate clinical trial within 30 day prior vaccination study drug , another clinical trial schedule study . 11 . Ca n't afford ready follow protocol 12 . Any criterion , judgment investigator , would interfere serf contraindication protocol adherence</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>vaccine</keyword>
	<keyword>ComBe Five</keyword>
	<keyword>Vietnam</keyword>
	<keyword>pentavalent</keyword>
</DOC>